



The Effect of Atorvastatin on Disease Activity & Severity in Plaque Psoriasis

¹Faraj A. Elsarah, ²Awad M. Alhasnony, and ³Haitham S. Alhosni

Faculty of Medicine, Ajdabiya University, Libya.

Faculty of Medicine, Tobruk University, Libya.

Faculty of Medicine, Derna University, Libya.

*Corresponding Author: E-mail Addresses: awad.muftah75@gmail.com

Volume: 1

Issue: 2

Page Number: 127 - 132

Keywords:

Psoriasis; Dyslipidaemia;
Atorvastatin; Atherosclerosis;
Antipsoriatic

Copyright: © 2024 by the authors.
Licensee The Afro-Asian Journal
of Scientific Research (AAJSR).
This article is an open access
article distributed under the terms
and conditions of the Creative
Commons Attribution (CC BY)
License
(<https://creativecommons.org/licenses/by/4.0/>).



Received: 11\10\2023

Accepted: 13\11\2023

Published: 30\12\2023

<https://doi.org/...../.....vixix>.

XXXX

ABSTRACT

As soon as regarded as simply a chronic inflammatory skin disorder, Psoriasis is now diagnosed as a systemic illness related to each immune and metabolic strategy. This situation affects approximately 2-3% of people internationally. Among the diverse health issues related to psoriasis, ordinary lipid degrees (dyslipidemia) have emerged as a fantastic concurrent circumstance. curiously, medicines referred to as statins, generally used to reduce cholesterol, show the ability to treat autoimmune disorders like psoriasis. That is because of their potential to lessen irritation and regulate immune responses, similar to their lipid-lowering effects.

1. INTRODUCTION

Psoriasis, a persistent autoimmune skin condition characterized utilizing persistent infection, influences 2-three% of the populace. it's believed to result from a combination of genetic predisposition and environmental factors. treatment alternatives encompass topical steroids, diet D3, tar, anthralin, retinoids, phototherapy, methotrexate, biologics, and others. notwithstanding those remedies, psoriasis frequently recurs, making its diagnosis uncertain. (Reich K et al., 2012).

Statins, mostly used for hyperlipidemia management, have proven immunomodulatory effects doubtlessly beneficial for psoriasis patients. (Mosiewicz J et al., 2013). (Grundy SM et al., 2002). these pills inhibit three-hydroxy-3-methylglutaryl coenzyme-A reductase, a key enzyme in LDL cholesterol synthesis. beyond reducing arterial inflammation, statins affect Th1-mediated immune responses, inhibit the most important histocompatibility complicated elegance II expression, prevent cytokine launch from mast cells, impede mast cellular degranulation, and disrupt pro-inflammatory chemokine interactions. (Egesi A et al.,2010) (Jowkar F et al., 2010). Psoriasis is associated with numerous comorbidities together with dyslipidemia, cardiovascular abnormalities, high blood pressure, atherosclerosis, type 2 diabetes, and obesity. recent observations highlight accelerated cardiovascular disease threats in psoriasis patients, which include acute coronary syndromes and hypertension. higher fees of hyperlipidemia, obesity, and type 2 diabetes were noted in psoriatic patients compared to government agencies. (Pietrzak A et al.,2010) (Gisoni P et al.,2018). inside the pores and skin, statins sell Th1-mediated immune responses, suppress essential histocompatibility complicated magnificence II induction, inhibit mast mobile cytokine launch and degranulation, and disrupt seasoned-inflammatory chemokine interactions. those consequences contribute to their ability to therapeutic position psoriasis control (Weitz-Schmidt G. et al., 2001).

The goal of the take a look at:

They take a look at pursuits to determine the prevalence of dyslipidemia in psoriatic sufferers as well as whether the addition of atorvastatin to conventional topical ant-psoriatic remedy can enhance skin lesions in psoriatic patients.

2. METHOD

In this study, 60 psoriasis patients were recruited to assess their lipid levels and disease severity scores. The participants were then split into two treatment groups to evaluate atorvastatin's impact on psoriasis severity using PASI and BSA scores.

The study enrolled patients:

Over 18 years old from the dermatology outpatient clinic at Ahmed Al-Magarif Central Teaching Hospital in Ajdabiya, Libya.

Exclusion criteria encompassed conditions affecting lipid profiles, endothelial function, and arterial stiffness, such as diabetes, hypothyroidism, liver or kidney disorders, Cushing's syndrome, obesity (BMI > 30), current smoking, familial dyslipidemia history, recent myocardial infarction, malignancies, and seizure disorders.

Patients using medications that influence lipid metabolism were also excluded, including those on lipid-lowering drugs, high-dose oral prednisolone, beta-blockers, hormonal contraceptives, thyroxine, and vitamin E.

Additionally, individuals who had used psoriasis treatments in the past month, as well as pregnant and breastfeeding women, were omitted.

The participants were divided into two 30-patient treatment groups. Subgroup 1 received atorvastatin (40 mg daily, split into two doses) and topical psoriasis treatment, while subgroup 2 was given only the topical regimen.

Statistical analysis:

Data were expressed as the means \pm SDs and the ratio. Statistical analysis was performed using Epi Info™ (Epi Info™ version 3.5.1 for Windows; CDC). The data were analyzed using Wilcoxon and Mann-Whitney tests, Chi-square, and two-tailed Student's tests. A, P value < 0.05 was considered statistically significant.

3. ETHIC APPROVAL

Approval was received from the local studies Ethics Committee, and written knowledgeable consent was acquired from every participant. evaluation of the sufferers changed into executed before and 4 months after treatment.

4. RESULT

We found that the rate of dyslipidemia was higher than the normal range. Also, the PASI and BSA scores reduction in the combined atorvastatin and topical group was significantly different from that in topical treatment only. Table (1): Baseline patient characteristics.

The lipid-decreasing properties of statins are broadly recognized. In specific affected person populations, along with people with non-dialysis-established continual kidney disorder or HIV infection, using statins is usually recommended for cardiovascular disorders prevention. Two meta-analyses have tested that oral statin therapy can potentially reduce the severity of psoriatic lesions within simply eight weeks. Each research related to simvastatin mentioned a lower in psoriasis severity, while research evaluating statins to placebo did not examine any huge consequences. (Weitz-Schmidt G et al., 2001).

5. DISCUSSION

This looks at examined 60 psoriasis patients, equally divided into two remedy agencies. The first group acquired a mixture of topical treatment and atorvastatin, at the same time as the second organization was administered topical treatment alone. Evaluation of the effects showed that the 2 organizations have been similar in terms of age, gender, and BMI (desk 1). The researchers employed the National Cholesterol Education Application's (NCEP) Adult Treatment Panel III (ATP-III) hints, in the beginning published in 2001 and up to date in 2004, to manage hypercholesterolemia. these pointers outline the following thresholds: general l dl cholesterol ≥ 6.20 mm/L, triglycerides ≥ 2.26 mm/L, LDL-C ≥ 14 mm/L, and HDL-C < 1.03 mm/L.

A look at demonstrated that patients receiving atorvastatin alongside topical steroid ointment showed marked decreases in cholesterol, triglyceride, and LDL-C ranges, with HDL-C closing stable. This shows atorvastatin's efficacy in coping with dyslipidemia. Substantially, we also located that atorvastatin remedy stepped forward both PASI and BSA scores in psoriasis patients, an unanticipated advantage. (Ghazizadeh R et al., 2011).

A separate have a look at found that treating plaque psoriasis for four months with calcipotriol/betamethasone di-propionate steroid ointment led to vast upgrades in PASI and BSA scores. (Shirinsky IV, et al, 2007) Our studies similarly found out that sufferers taking oral atorvastatin similarly to topical remedy experienced an extra fast and stated discount in PASI and BSA ratings as compared to the ones receiving topical treatment by myself. (Al-Shimary AM et al.,2018).

The initial PASI score for Institution 1 turned to 111.9 ± 7.4 , which drastically decreased to 5.9 ± 1.4 ($p < 0.01$) after 6 weeks of remedy. BSA reduced from 10.1 ± 2.4 to 6.9 ± 2.4 ($p < 0.01$). Conversely, the non-atorvastatin group showed no sizable PASI or BSA reduction.

This shows that adding atorvastatin 40 mg/d) to topical remedy substantially progressed psoriasis management. Statins' 07b031025f5f96dfa8443f843db463b6 and immunomodulatory results had been identified inside the Nineties as capacity psoriasis treatments.

Research outcomes are numerous, with some research locating no substantial impact and others suggesting advantages for psoriasis and other skin situations.

The hypothesis centered on statins inhibiting LFA-1-mediated leukocyte adhesion to ICAM-1 and suppressing seasoned-anti-inflammatory mediator manufacturing. (Trong HN, et al, 2019)

A couple of l dl cholesterol-modulating mechanisms have shown positive consequences on psoriatic lesions.

Those Include: LFA-1 downregulation, decreased leukocyte-endothelial adhesion, altered extravasation and herbal killer cellular feature, suppression of pro-anti-inflammatory cytokines like TNF-alpha and interleukins-1 and -6, reduced C-reactive protein, promotion of Th1 to Th2 mobile shift, and inhibition of Th1 cytokine receptors on T cells. (Al Salman M et al., 2021).

Those tactics restrict lymphocyte activation and next infiltration into skin lesions, mainly to enhancements in plaque psoriasis. that is pondered in decreased Psoriasis vicinity and Severity Index (PASI) and body surface region (BSA) rankings, indicating decreased disorder severity and volume. (Shirinsky IV et al., 2007).

Naseri et al. performed a double-blind look at with 30 plaque psoriasis sufferers split into corporations. The first institution acquired oral statin (forty mg/day) plus topical steroid (50% betamethasone in petrolatum) for eight weeks, at the same time as the second group were given an oral placebo with the same topical steroid. (Iraji F, et al. 2014).

consequences showed widespread PASI rating reductions in both organizations, with a more said decrease inside the simvastatin institution, corroborating our findings. Moreover, Wolkenstein et al.'s observation indicated that oral statin use was related to a decreased risk of psoriasis development. (Faghihi T et al.,2011).

Table (1): Baseline patient characteristics.

	Group 1 (combined ttt)	Group 2(topical ttt only)
Age	32.26± 3.15	37.26± 4.25
Sex (male/female)	2/28	6 /24
Duration of disease	14.50±4.1	13.60±2.6
BSA	10.1± 2.4	10.5 ± 1.4
PASI score	10.9 ± 7.4	11.9 ± 6.4
TC	224.66±31.12	228.13 ±11.75
TG	137.33±47.31	126.93±31.97
LDL	142.33± 24.41	142.66±24.33
HDL	44.06±9.12	41.60±10.85
TC/HDL-C	5.31±1.38	5.75±1.44
LDL-C/HDL-C	3.40± 1.03	3.56±0.82

Table (2): Effect of treatment on disease activity, severity scores, & lipid profile.

	Group 1: Before	Group 1: After	Group 2: Before	Group 2: After	Significance between drugs
BSA	10.1± 2.4	6.9 ± 2.4	10.5 ± 1.4	9.9 ± 7.4	P < 0.001
PASI	11.9 ± 7.4	5.8 ± 1.4	11.9 ± 6.4	7.9 ± 7.2	P < 0.01
TC	224.66±31.12	191.80±12.77	228.13 ±11.75	291.71±10.67	P < 0.05
TG	137.33±47.31	97.10±11.77	196.93±31.97	194.80±11.17	P < 0.001
LDL	142.33± 24.41	91.80±12.65	142.66±24.33	141.80±12.77	P < 0.01
HDL	44.06±9.12	61.50±10.65	41.60±10.85	51.80±11.33	P < 0.01
TC/HDL-C/ LDL-C/HDL-C	5.31±1.38 3.40± 1.03	3.41±1.38 2.52± 1.13	5.75±1.44 3.56±0.82	4.31±1.16 3.00± 1.63	P < 0.01

6. CONCLUSION

The addition of atorvastatin may additionally enlarge the efficacy of topical remedies in managing psoriasis. Given statins' safety profile and capacity benefits, further research into their twin-movement consequences in psoriasis remedy is warranted. Those outcomes encompass both reducing atherosclerotic disease burden via lipid discount and diminishing psoriatic disorder interest through 07b031025f5f96dfa8443f843db463b6 and immunomodulatory mechanisms.

7. REFERENCES

- Al Salman M, Ghiasi M, Farid AS, Taraz M, Azizpour A, Mahmoudi H. (2021). Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: a randomized controlled trial. *Dermatol Ther.* 34, e15075. doi: 10.1111/dth. 15075
- Al-Shimary AM, Al-Dujaly SN, Al-Hattab MK. (2018). Effect of oral simvastatin therapy on patients with plaque psoriasis treated with potent topical steroid. *Indian J Public Health Res Dev.* (9),776–8.
- Egesi A, Sun G, Khachemoune A, Rashid RM. (2010). Statins in skin: research and rediscovery, from psoriasis to sclerosis. *Journal of drugs in dermatology: JDD.*; 9(8),921-7. PMID:20684142.
- Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M. (2011). Atorvastatin for the treatment of plaque-type psoriasis. *Pharmacotherapy.* (31),1045–50.
- Ghazizadeh R, Tosa M, Ghazizadeh M. (2011). Clinical improvement in psoriasis with treatment of associated hyperlipidemia. *The American journal of the medical sciences,* 341(5),394-8.
- Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. (2018). Psoriasis and the metabolic syndrome. *Clinics in dermatology,* 36(1),21-8.
- Greenwood J, Steinman L, Zamvil SS. (2006). Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. *Nature Reviews Immunolog,* 6(5),358- 370.
- Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard J, Hunninghake DB, Illingworth DR, Luepker RV, McBride P, McKenney JM. (2002). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *Circulation.*; 106(25),3143-421.
- Iraji F, Tajmirrahi N, Siadat AH, Momeni I, Nilforoushzadeh MA. (2014). Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis. *Adv Biomed Res.* 3,11. doi: 10.4103/2277-9175.124639.
- Jowkar F, Namazi MR. (2010). Statins in dermatology. *International journal of dermatology;* 49(11),1235-43.
- Mosiewicz J, Pietrzak A, Chodorowska G, et al., (2013). The rationale for statin uses in psoriatic patients. *Archives of dermatological research.*; 305(6),467-472.
- Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. (2010). Lipid disturbances in psoriasis: an update. *Mediators of inflammation.*

Reich K. (2012). The concept of psoriasis as a systemic inflammation: implications for disease management. *Journal of the European Academy of Dermatology and Venereology*. ;(26),3-11.

Shirinsky IV, Shirinsky VS. (2007). Efficacy of simvastatin in plaque psoriasis: A pilot study. *Journal of the American Academy of Dermatology*, 57(3),529-31.

Shirinsky IV, Shirinsky VS. (2007). Efficacy of simvastatin in plaque psoriasis: a pilot study. *J Am Acad Dermatol*. (57),529–31. doi: 10.1016/j.jaad.2007. 05.040.

Trong HN, Tat TN, Anh TTN, Uyen NP, Van TN, Hau KT, et al., (2019). Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: the Vietnamese experience. *Open Access Maced J Med Sci*. 7,237–42. doi: 10.3889/oamjms. 2019.060.

Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. *Nature medicine*, 7(6),687.